Alphatec (NASDAQ:ATEC) EVP David Sponsel Sells 2,555 Shares of Stock

Key Points

• David Sponsel, EVP of Alphatec, sold 2,555 shares of stock for $39,193.70, reducing his ownership by 0.48% while retaining 531,861 shares valued at over $8 million.
• Alphatec reported a 27.5% year-over-year increase in revenue to $185.54 million for the recent quarter, beating analysts' expectations and posting $0.02 earnings per share.
• Analysts are optimistic about Alphatec, with multiple buy ratings issued and price targets ranging from $18.00 to $22.00, indicating potential growth in the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 2,555 shares of the business's stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $15.34, for a total value of $39,193.70. Following the transaction, the executive vice president directly owned 531,861 shares in the company, valued at $8,158,747.74. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

David Sponsel also recently made the following trade(s):

• On Thursday, September 18th, David Sponsel sold 137,445 shares of Alphatec stock. The shares were sold at an average price of $15.09, for a total value of $2,074,045.05.

Alphatec Stock Performance

ATEC traded up $0.32 during trading on Friday, reaching $15.54. 2,658,987 shares of the company were exchanged, compared to its average volume of 1,928,332. The stock has a market cap of $2.30 billion, a P/E ratio of -13.75 and a beta of 1.02. The firm has a 50 day moving average of $14.23 and a 200 day moving average of $12.19. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $16.70.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter last year, the business posted ($0.29) earnings per share. The company's quarterly revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ATEC has been the topic of a number of recent analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 1st. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a report on Monday, June 16th. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a research note on Sunday, September 7th. Finally, Barclays reaffirmed an "overweight" rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $18.50.

Hedge Funds Weigh In On Alphatec

Several hedge funds have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in Alphatec in the fourth quarter valued at about $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Alphatec by 3.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,809 shares of the medical technology company's stock valued at $650,000 after acquiring an additional 2,177 shares during the period. Nuveen Asset Management LLC grew its stake in Alphatec by 78.4% in the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock valued at $23,730,000 after acquiring an additional 1,136,330 shares during the period. Man Group plc boosted its position in shares of Alphatec by 74.5% during the fourth quarter. Man Group plc now owns 27,330 shares of the medical technology company's stock worth $251,000 after buying an additional 11,666 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Alphatec by 51.1% during the fourth quarter. ProShare Advisors LLC now owns 29,319 shares of the medical technology company's stock worth $269,000 after buying an additional 9,920 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.